Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rech

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Science Translational Medicine|November 9, 2022
BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustionIn-Young Jung, Vivek Narayan, Sierra McDonald, et al.
Cancer Discovery|April 3, 2023
Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell-Intrinsic DysfunctionIn-Young Jung, Robert L Bartoszek, Andrew J Rech, et al.
Zeitschrift Fur Rheumatologie|November 6, 2020
[S2k guidelines (executive summary): management of large-vessel vasculitis]J H Schirmer, P M Aries, K Balzer, et al.
Zeitschrift Fur Rheumatologie|November 6, 2020
[S2k guidelines: management of large-vessel vasculitis]J H Schirmer, P M Aries, K Balzer, et al.
Nature|March 11, 2015
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancerChristina Twyman-Saint Victor, Andrew J Rech, Amit Maity, et al.
Immunity|July 1, 2018
Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to ImmunotherapyJinyang Li, Katelyn T Byrne, Fangxue Yan, et al.
Cell Reports. Medicine|August 19, 2025
Clinical and molecular dissection of CAR T cell resistance in pancreatic cancerM Angela Aznar, Charly R Good, Julie S Barber-Rotenberg, et al.
Nature Medicine|June 1, 2025
Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trialStephen J Bagley, Arati S Desai, Joseph A Fraietta, et al.
Nature Medicine|June 11, 2025
Author Correction: Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trialStephen J Bagley, Arati S Desai, Joseph A Fraietta, et al.
Nature Biomedical Engineering|March 10, 2026
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancerGregory M Chen, Ankita Jain, David T Gering, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Science Translational Medicine|November 9, 2022
BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustionIn-Young Jung, Vivek Narayan, Sierra McDonald, et al.
Cancer Discovery|April 3, 2023
Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell-Intrinsic DysfunctionIn-Young Jung, Robert L Bartoszek, Andrew J Rech, et al.
Zeitschrift Fur Rheumatologie|November 6, 2020
[S2k guidelines (executive summary): management of large-vessel vasculitis]J H Schirmer, P M Aries, K Balzer, et al.
Zeitschrift Fur Rheumatologie|November 6, 2020
[S2k guidelines: management of large-vessel vasculitis]J H Schirmer, P M Aries, K Balzer, et al.
Nature|March 11, 2015
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancerChristina Twyman-Saint Victor, Andrew J Rech, Amit Maity, et al.
Immunity|July 1, 2018
Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to ImmunotherapyJinyang Li, Katelyn T Byrne, Fangxue Yan, et al.
Cell Reports. Medicine|August 19, 2025
Clinical and molecular dissection of CAR T cell resistance in pancreatic cancerM Angela Aznar, Charly R Good, Julie S Barber-Rotenberg, et al.
Nature Medicine|June 1, 2025
Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trialStephen J Bagley, Arati S Desai, Joseph A Fraietta, et al.
Nature Medicine|June 11, 2025
Author Correction: Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trialStephen J Bagley, Arati S Desai, Joseph A Fraietta, et al.
Nature Biomedical Engineering|March 10, 2026
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancerGregory M Chen, Ankita Jain, David T Gering, et al.
Pageof 10